Migalastat Chaperone Therapy for Mutation-Specific Fabry Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy (ERT), face challenges such as rapid degradation of infused proteins, high costs, and inability to penetrate certain areas, while substrate reduction therapy and pharmacological chaperones like migalastat are not universally effective due to unpredictable patient responses based on specific GLA gene mutations.
Innovation Solution
Administering a therapeutically effective dose of migalastat, specifically tailored for patients with missense mutations in the α-Gal A gene, to stabilize and enhance the activity of the mutant enzyme, allowing it to traffic out of the ER and reduce substrate accumulation in tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation is reduced, but the therapy faces rapid degradation of infused proteins, high costs, and inability to penetrate certain tissues
Solution Approach 1:
The patent uses a pharmacological chaperone (migalastat) as an intermediary molecule that binds to mutant α-Gal A enzymes to stabilize them and facilitate their proper folding and trafficking. This mediator approach avoids the need for complex intravenous enzyme replacement therapy while achieving similar therapeutic effects through oral administration.
Solution Approach 2:
Instead of replacing the defective enzyme with a complex purified wild-type protein (ERT), the patent uses a small molecule pharmacological chaperone that copies or mimics the stabilizing effect of the wild-type enzyme on the mutant protein, simplifying the therapy from protein replacement to small molecule administration.
2Reliability
If pharmacological chaperones like migalastat are used to stabilize mutant enzymes, then enzyme activity is enhanced, but patient response is unpredictable based on specific GLA gene mutations
Solution Approach 1:
The patent segments the population of Fabry disease patients based on their specific GLA gene mutations, identifying subgroups with missense mutations that are responsive to pharmacological chaperones. This segmentation allows for targeted therapy selection, matching specific mutation types with appropriate treatment approaches.
Solution Approach 2:
The patent applies local quality by tailoring the pharmacological chaperone therapy to specific mutation types (missense mutations in the catalytic domain), rather than applying a universal treatment to all Fabry patients. The therapy's effectiveness varies by local mutation characteristics.
3Quantity of substance
If small molecule inhibitors are used for substrate reduction therapy, then substrate production is decreased, but the approach is not universally effective for all enzyme deficiencies
Solution Approach 1:
Instead of using small molecule inhibitors to block substrate production (substrate reduction therapy), the patent inverts the approach by using pharmacological chaperones to enhance the function of existing mutant enzymes, allowing them to process substrates more effectively despite the genetic mutation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Migalastat effectively stabilizes mutant α-Gal A enzymes in patients with specific GLA gene mutations, enhancing enzyme activity and reducing substrate accumulation in tissues, thereby treating Fabry disease more effectively than existing therapies.
Implementation Method 1
Such PCs include small molecule inhibitors of α-Gal A, which can bind to the α-Gal A to increase the stability of both mutant enzyme and the corresponding wild type
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.